快速多重PCR对产ESBL肠杆菌科直肠定植患者通气医院获得性肺炎诊断与治疗的影响
这项单中心前瞻性研究纳入2020年3月至2022年8月ICU收治的294例产ESBL肠杆菌科(ESBL-E)直肠定植患者,其中168例(57%)接受机械通气。在41例疑似VAP/vHAP发作中,mPCR检出blaCTX-M基因15/41(37%),其中9/15(60%)经培养证实为ESBL-E所致肺炎;培养与blaCTX-M结果一致35/41(85%),26例blaCTX-M阴性者培养均未检出ESBL-E。在95例确诊VAP/vHAP中(22例行mPCR,73例未行),行mPCR与更高的充足经验性抗生素治疗处方率相关,多因素logistic回归aOR 7.5(95%CI 2.1-35.9),p=0.004。
要点
- 在ESBL-E直肠定植、疑似VAP/vHAP患者中,mPCR blaCTX-M与培养结果一致35/41(85%),26例blaCTX-M阴性者培养均未检出ESBL-E,阴性结果有助于排除ESBL-E相关肺炎。
- mPCR检出blaCTX-M的15例中,仅9例(60%)培养证实为ESBL-E所致肺炎。
- 在95例确诊VAP/vHAP中(22例行mPCR,73例未行),mPCR与更高的充足经验性抗生素处方率相关:多因素logistic回归aOR 7.5(95%CI 2.1-35.9),p=0.004;倾向性加权aOR 5.9(95%CI 1.6-22.1),p=0.008;匹配队列aOR 5.8(95%CI 1.5-22.1),p=0.01。
- 在确诊VAP/vHAP的95例中,47例(49%)为ESBL-E所致,24例(25%)为碳青霉烯耐药菌所致。
- 若在肺炎临床验前概率极低时使用mPCR,由于高敏感性和肺炎过度诊断率,碳青霉烯过度使用的风险可能占主导(作者认为)。
适用人群与场景
- ICU收治的产ESBL肠杆菌科(ESBL-E)直肠定植患者,2020年3月至2022年8月单中心前瞻性研究;294例ESBL-E定植患者中168例(57%)接受机械通气。
- 疑似VAP/vHAP发作的ESBL-E定植患者(诊断性能分析41例次;影响分析为确诊VAP/vHAP 95例次)。
研究设计与关键结果
- 单中心前瞻性研究,2020年3月至2022年8月,纳入294例ESBL-E直肠定植ICU患者,其中168例(57%)机械通气。
- 诊断性能:41例次疑似VAP/vHAP中,mPCR检出blaCTX-M 15/41(37%),其中9/15(60%)培养证实为ESBL-E所致肺炎;培养与blaCTX-M一致35/41(85%);26例blaCTX-M阴性者培养均未检出ESBL-E。
- 影响分析:95例次确诊VAP/vHAP中22例次行mPCR、73例次未行;47例次(49%)为ESBL-E所致,24例次(25%)为碳青霉烯耐药菌所致。
- mPCR与更高充足经验性抗生素治疗处方率相关:多因素logistic回归aOR 7.5(95%CI 2.1-35.9),p=0.004;倾向性加权aOR 5.9(95%CI 1.6-22.1),p=0.008;匹配队列aOR 5.8(95%CI 1.5-22.1),p=0.01。
证据类型、等级与局限
- 证据类型:单中心前瞻性研究。
- 局限:原文报告需进一步研究(Further studies are warranted);作者指出若在肺炎临床验前概率极低时使用mPCR,由于高敏感性和肺炎过度诊断率,碳青霉烯过度使用风险可能占主导。
对床旁实践的改变
- 作者认为,对ESBL-E直肠定植、疑似VAP/vHAP患者,呼吸道样本行mPCR似乎是有前景的工具;mPCR blaCTX-M阴性有助于排除ESBL-E相关肺炎。
- 作者认为,在确诊VAP/vHAP患者中,基于mPCR的抗生素治疗与更高的充足经验性抗生素处方率相关。
- 作者指出,若在肺炎临床验前概率极低时使用mPCR,由于高敏感性和肺炎过度诊断率,碳青霉烯过度使用的风险可能占主导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Antimicrobial stewardship (AMS) for ventilator-associated pneumonia (VAP) or ventilated hospital-acquired pneumonia (vHAP) in extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) carriers is challenging. BioFire® FilmArray® Pneumonia plus Panel (mPCR) can detect bacteria and antibiotic resistance genes, including blaCTX-M, the most common ESBL-encoding gene.
METHODS: This monocentric, prospective study was conducted on a group of ESBL-E carriers from March 2020 to August 2022. The primary objective was to evaluate the concordance between the results of mPCR and conventional culture performed on respiratory samples of ESBL-E carriers to investigate suspected VAP/vHAP. The secondary objective was to appraise the impact of performing or not mPCR on initial antibiotic therapy adequacy in ESBL-E carriers with confirmed VAP/vHAP.
RESULTS: Over the study period, 294 patients with ESBL-E carriage were admitted to the ICU, of who 168 (57%) were mechanically ventilated. (i) Diagnostic performance of mPCR was evaluated in suspected 41 episodes of VAP/vHAP: blaCTX-M gene was detected in 15/41 (37%) episodes, where 9/15 (60%) were confirmed ESBL-E-induced pneumonia. The culture and blaCTX-M were concordant in 35/41 (85%) episodes, and in all episodes where blaCTX-M was negative (n = 26), the culture never detected ESBL-E. (ii) The impact of mPCR on initial antibiotic therapy adequacy was assessed in 95 episodes of confirmed VAP/vHAP (22 episodes were tested with mPCR and 73 without); 47 (49%) episodes were ESBL-E-induced, and 24 (25%) were carbapenem-resistant bacteria-induced. The use of mPCR was significantly associated with higher prescription of adequate empirical antibiotic therapy in the multivariable logistic regression (adjusted odds ratio (aOR) (95% CI) of 7.5 (2.1-35.9), p = 0.004), propensity-weighting (aOR of 5.9 (1.6-22.1), p = 0.008), and matching-cohort models (aOR of 5.8 (1.5-22.1), p = 0.01).
CONCLUSION: mPCR blaCTX-M showed an excellent diagnostic value to rule out the diagnosis of ESBL-E related pneumonia in ESBL-E carriers with suspected VAP/vHAP. In addition, in patients with confirmed VAP/vHAP, a mPCR-based antibiotic therapy was associated with an increased prescription of adequate empirical antibiotic therapy. Performing mPCR on respiratory samples seems to be a promising tool in ESBL-E carriers with suspected vHAP/VAP. However, if mPCR is used in very low pre-test clinical probability of pneumonia, due to the high sensitivity and the rate of overdiagnosed pneumonia, the risk of overconsumption of carbapenem may prevail. Further studies are warranted.
参考来源
- Bay P, Fihman V, Woerther PL, et al. Performance and impact of rapid multiplex PCR on diagnosis and treatment of ventilated hospital-acquired pneumonia in patients with extended-spectrum β-lactamase-producing Enterobacterales rectal carriage. Ann Intensive Care. 2024. PMID: 39073627. doi:10.1186/s13613-024-01348-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。